BlackRock Group’s PDL BioPharma, Inc. PDLI Stock Holding History

BlackRock Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$581K	Sell	273,850 -58,359	-18%	-$163K	﹤0.01%	2309
2016 Q3	$1.11M	Buy	332,209 +15,840	+5%	+$50.3K	﹤0.01%	1975
2016 Q2	$993K	Buy	316,369 +169,089	+115%	+$564K	﹤0.01%	1979
2016 Q1	$490K	Sell	147,280 -102,823	-41%	-$321K	﹤0.01%	2247
2015 Q4	$885K	Sell	250,103 -127,686	-34%	-$534K	﹤0.01%	1968
2015 Q3	$1.9M	Buy	377,789 +31,059	+9%	+$178K	﹤0.01%	1524
2015 Q2	$2.23M	Buy	346,730 +31,993	+10%	+$214K	﹤0.01%	1497
2015 Q1	$2.21M	Buy	314,737 +50,970	+19%	+$369K	﹤0.01%	1434
2014 Q4	$2.04M	Sell	263,767 -43,683	-14%	-$346K	﹤0.01%	1463
2014 Q3	$2.3M	Buy	307,450 +6,948	+2%	+$64.5K	﹤0.01%	1366
2014 Q2	$2.91M	Buy	300,502 +79,391	+36%	+$708K	﹤0.01%	1308
2014 Q1	$1.84M	Buy	221,111 +19,349	+10%	+$166K	﹤0.01%	1627
2013 Q4	$1.7M	Sell	201,762 -19,884	-9%	-$168K	﹤0.01%	1635
2013 Q3	$1.77M	Buy	221,646 +20,091	+10%	+$162K	﹤0.01%	1538
2013 Q2	$1.56M	Buy	+201,555	New	+$1.57M	﹤0.01%	1438

Other funds holding PDLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock Group's PDLI Position: Q4 2016 in Review

BlackRock Group reduced its PDL BioPharma, Inc. (PDLI) stake by 18% in Q4 2016, selling an estimated $163K and leaving 273,850 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #2309.

BlackRock Group first reported a position in PDLI in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.91M in Q2 2014. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

BlackRock Group held 273,850 shares of PDL BioPharma, Inc. worth $581K as of Q4 2016.
BlackRock Group sold 58,359 PDL BioPharma, Inc. shares in Q4 2016, an estimated $163K.
PDL BioPharma, Inc. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2309 holding.
BlackRock Group first reported a position in PDL BioPharma, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Group's PDL BioPharma, Inc. position peaked at $2.91M in Q2 2014.
190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.